Insilico Medicine has joined forces with Menarini through its subsidiary Stemline Therapeutics to develop a small molecule KAT6A inhibitor to treat hormone-sensitive cancers, focusing on ER+/HER2- breast cancer. 

The collaboration involves an exclusive licensing agreement, providing Stemline with global rights to develop and commercialise a novel KAT6A inhibitor, which is designed using Insilico’s artificial intelligence (AI) platform.  

The molecule has shown positive results in preclinical studies, demonstrating a potent inhibition in multiple CDX and PDX models, as well as a good safety and efficacy profile. Insilico presented data on this development at the San Antonio Breast Cancer Symposium last month.  

Insilico will receive $12m in an upfront payment from Menarini, as well as milestone payments with a combined value of more than $500m and sales royalties. 

In September 2019, Insilico announced its AI-powered drug discovery system GENTRL, which was created in alliance with WuXi AppTec, a global open-access R&D and manufacturing platform, as well as professor Alán Aspuru-Guzik, who works in quantum computing and AI in chemistry. 

In the announcement accompanying the agreement, Menarini CEO Elcin Barker Ergun said: “Having brought the first innovation in endocrine therapy after almost 20 years to the US and Europe with elacestrant for ER+/HER2- breast cancer patients, our aim is to further augment patient outcomes, and targeting KAT6A can potentially serve that in breast cancer and beyond.” 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

KAT6A proteins play a crucial role in regulating gene expression and are implicated in various cancers, including poor clinical outcomes of ER+/HER- breast cancers.  

Other companies are also looking at the same protein inhibition. Pfizer’s PF-07248144 is under development for the treatment of locally advanced or metastatic ER+/HER2- breast cancer, metastatic castration-resistant prostate cancer and metastatic non-small cell lung cancer (NSCLC).  

According to GlobalData’s Pharmaceutical Intelligence Center, PF-07248144 is currently being investigated in a Phase I clinical trial, with a Phase II trial planned. 

GlobalData is the parent company of Pharmaceutical Technology.